RCT | Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden.

Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial – The Lancet (link to abstract – $ for full-text)

News Release: Treatment before patients develop rheumatism provides lasting relief – Leiden University Medical Centre

Commentaries on Twitter:

NEW in @TheLancet—The TREAT EARLIER trial shows that #methotrexate initiated in patients with arthralgia at risk of #rheumatoidarthritis did not prevent the development of clinical arthritis, but did modify the disease course https://t.co/5zh7lqb4NJ pic.twitter.com/lJflW9Prwm

— The Lancet Rheumatology (@TheLancetRheum) July 22, 2022

??Methotrexate,??study
MTX in pre-arthritis stage➡️ did not prevent the development of clinical arthritis
but ➡️sustained improvement in
♦️MRI-detected inflammation,
♦️Symptoms (Pain & EMS)
♦️Related impairments (HAQ n Presentism)
Vs placebohttps://t.co/I0IdKydPME pic.twitter.com/cNi6AhO151

— EnvisionRheumat (@ERheumat) July 29, 2022